Adverse events (AE)
Ten studies provided enough information on the occurrence of AEs. No statistically significant difference on the occurrence of AE was observed between the use of omalizumab vs. placebo (RR=1.03; 95% CI, 0.93, 1.14; p=0.618; I2 = 43.3%). (Figure 6). Supplementary Table III presents the AEs of the included trials classified in system organ classes based on Medical Dictionary for Regulatory Activities version 23 (MedDRA v.23). Serious AEs of the included trials are presented in Table 2.